# Protara Therapeutics, Inc. (TARA) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Protara Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TARA/mda/fy2025/): filed 2026-03-10; accession 0001213900-26-025433 (https://www.sec.gov/Archives/edgar/data/1359931/000121390026025433/ea0277639-10k_protara.htm); latest 10-K
- [FY 2024 MD&A](/company/TARA/mda/fy2024/): filed 2025-03-05; accession 0001213900-25-020368 (https://www.sec.gov/Archives/edgar/data/1359931/000121390025020368/ea0231646-10k_protara.htm)
- [FY 2023 MD&A](/company/TARA/mda/fy2023/): filed 2024-03-13; accession 0001213900-24-021982 (https://www.sec.gov/Archives/edgar/data/1359931/000121390024021982/f10k2023_protarathera.htm)
- [FY 2022 MD&A](/company/TARA/mda/fy2022/): filed 2023-03-08; accession 0001213900-23-018373 (https://www.sec.gov/Archives/edgar/data/1359931/000121390023018373/f10k2022_protarathera.htm)
- [FY 2021 MD&A](/company/TARA/mda/fy2021/): filed 2022-03-09; accession 0001213900-22-011208 (https://www.sec.gov/Archives/edgar/data/1359931/000121390022011208/f10k2021_protarathera.htm)

Back to /company/TARA/